Capsule Sponge + Biomarkers Can Stratify Risk in Barrett Esophagus
By Elana Gotkine HealthDay Reporter
MONDAY, June 30, 2025 -- In adult patients with nondysplastic Barrett esophagus at last endoscopy, a subsequent capsule-sponge test can assist in identifying those at highest risk of dysplasia or cancer, according to a study published online June 23 in The Lancet.
W. Keith Tan, M.B.Ch.B., from Cambridge University in the United Kingdom, and colleagues prospectively evaluated a prespecified risk stratification tool -- comprising a pan-esophageal cell collection device coupled with biomarkers -- to establish whether it can identify those at highest risk of dysplasia or cancer. Adult patients with nondysplastic Barrett esophagus at their last endoscopy had a capsule-sponge test and were assigned as low, moderate, or high risk.
A total of 910 patients were recruited, 15, 31, and 54 percent were classified as high, moderate, and low risk, respectively. The researchers found that in the high-risk group, the positive predictive value for any dysplasia or worse was 37.7 percent. The highest risk of high-grade dysplasia or cancer was seen for patients with both atypia and aberrant p53 (relative risk, 135.8 relative to the low-risk group). In the low-risk group, the prevalence of high-grade dysplasia or cancer was 0.4 percent; the negative predictive value was 97.8 percent for any dysplasia or cancer. The proportion needing p53 pathology review could be reduced to 32 percent, without missing any positive cases, by applying a machine learning algorithm as part of a digital pathology workflow.
"The capsule sponge can be administered easily and quickly by nurses with only limited training required and will not need to take up precious endoscopy resources," Tan said in a statement.
Several authors who are named on patents related to this test disclosed ties to Cyted Health and Medtronic. Medtronic holds the license for the cytosponge technology.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Updated Guidance Improves Staging of HPV-Positive Oropharyngeal Cancer
MONDAY, July 21, 2025 -- Version nine of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control staging system (AJCC9V) human papillomavirus...
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.